Tecentriq (atezolizumab)

pCPA File Number: 21167
Negotiation Status:
Concluded with an LOI
For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity
Hoffmann-La Roche
CDA-AMC Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: